Navigation Links
Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
Date:1/7/2009

SOUTH SAN FRANCISCO, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that the Company will present data from two ongoing Phase 2 clinical trials of picoplatin at two upcoming American Society of Clinical Oncology (ASCO) Symposia.

In January, the Company will present updated data from its Phase 2 trial of picoplatin in patients with metastatic colorectal cancer at ASCO's 2009 Gastrointestinal (GI) Cancers Symposium in San Francisco. In February, updated data from the ongoing Phase 2 trial of picoplatin in patients with metastatic hormone refractory (or castration resistant) prostate cancer will be presented at ASCO's Genitourinary (GU) Cancers Symposium in Orlando, Fla.

    Presentation details are as follows:
    --  The ASCO 2009 GI Cancers Symposium, San Francisco
        --  Randomized Phase 2 study of picoplatin in combination with
            5-fluorouracil and leucovorin (FOLPI) as a neuropathy-sparing
            alternative to mFOLFOX-6 as first-line therapy for colorectal
            cancer (CRC)
        --  R. H. Earhart, S. V. Cheporov, O. A. Gladkov, M. Y. Biakhov, G. S.
            Baker, H. B. Breitz
        --  Saturday, January 17, 12:30-1:30

    --  The ASCO 2009 GU Cancers Symposium, Orlando, Fla.
        --  Results of a Phase 2 study of picoplatin with docetaxel and
            prednisone in first-line treatment of metastatic hormone
            refractory prostate cancer (HRPC)
        --  R. Earhart, L. Roman, N. Lopatkin, P. Karlov,  H. Breitz, David
            Karlin, R. De Jager
        --  Friday, February 27, 11:45-1:15

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on th
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
2. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
3. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
4. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
5. Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
6. Poniard Pharmaceuticals Announces Upcoming Conference Participation
7. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
8. Poniard Pharmaceuticals Announces Upcoming Conference Participation
9. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
10. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
11. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2012)... a timely and reliable way to obtain enough raw ... the tissue they need to build. In a new ... viscosity, and other mechanical properties of adult stem cells ... whether they will turn into bone, cartilage, or fat. ... of extracting the needed cells from a larger and ...
(Date:5/21/2012)... Elsevier,s Computers & Graphics announces the upcoming ... which will incorporate the Collage Authoring Environment, a workflow ... of the 2011 Executable Paper Grand Challenge. The call ... Eurographics 2012 on May 13, during the 3DOR Workshop. ... to embed chunks of executable code and data into ...
(Date:5/21/2012)... International scientific and government experts held a ... use of Oxitec,s genetically modified Aedes aegypti ... Panama. The independent forum was co-organised by ... Institute for Health Studies and the University of Panama. ... institutes as well as the Pan American Health Organisation, ...
(Date:5/18/2012)...  Intellect Neurosciences, Inc. (OTCPK: ILNS) announces that ... CEO, will be presenting at the Seventh Annual ... (Logo:  http://photos.prnewswire.com/prnh/20111214/NY22484LOGO ) The title ... Offer Attractive Targets for Active and Passive Immunotherapy." ... at the Intercontinental Hotel in Boston from 10:15-11:30 ...
Breaking Biology Technology:Physical properties predict stem cell outcome 2Physical properties predict stem cell outcome 3Expert Meeting Discusses Testing of Oxitec Transgenic Mosquitoes in Panama 2Expert Meeting Discusses Testing of Oxitec Transgenic Mosquitoes in Panama 3Intellect Neurosciences, Inc. to Present at Neurotech Investing and Partnering Conference 2Intellect Neurosciences, Inc. to Present at Neurotech Investing and Partnering Conference 3
... Inc. (Nasdaq: AMLN ) confirmed today that it ... and affiliated funds announcing their intent to nominate a slate ... 2009 annual meeting. The notice from the Icahn group ... approval requesting that the Company reincorporate in the state of ...
... NEOG ) announced the appointment of ... this newly created position, Dr. Rice will have,responsibility ... , "Dr. Rice brings ... said James Herbert, Neogen,s chief executive officer. "She ...
... Mass., Jan. 30 Jeff Olson, Manager of Nucleic ... Enrichment of Genomic Loci for Targeted Sequencing Applications ... RainStorm micro-droplet technology on the new RDT 1000 instrument, ... (AGBT) conference on Friday, February 6th, in Marco Island, ...
Other Biology Technology:Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices 2Neogen Names New Senior Science Officer; Added to S&P Index 2'Enrichment of Genomic Loci for Targeted Sequencing Application' Is Focus of 2009 AGBT Conference Workshop 2'Enrichment of Genomic Loci for Targeted Sequencing Application' Is Focus of 2009 AGBT Conference Workshop 3
(Date:5/20/2012)... A team of researchers from UCSF and UC San ... effective against amoebas in lab and animal studies, suggesting ... the amoebic infections that cause human dysentery throughout the ... has received Orphan Drug Status for the drug, known ... and has applied for approval to start clinical trials ...
(Date:5/20/2012)... and Cancer Research Group headed by Dr Hctor ... Oncology (VHIO) has identified the molecular mechanisms that ... clinical trials for colon cancer treatment. The study ... with Professor Alberto Muozs laboratory at the Instituto ... Investigaciones Cientficas (IIB-CSIC-Madrid). Published today in Nature ...
(Date:5/18/2012)... /PRNewswire-iReach/ -- With chronic diseases continuing ... sight, and research to find "cures" continuing to ... remain "a few years away," a small but ... place: the human consciousness. A number of healing ... sacred geometry, and intention, have emerged, embracing practices ...
Breaking Biology News(10 mins):Lab tests show arthritis drug effective against global parasite 2Lab tests show arthritis drug effective against global parasite 3Lab tests show arthritis drug effective against global parasite 4Discovery of mechanisms predicting response to new treatments in colon cancer 2Discovery of mechanisms predicting response to new treatments in colon cancer 3Healing Method from Australia Addresses the Human Genome 2Parallel brainstem circuit discovery suggests new path in Parkinsons research 13525 1Parallel brainstem circuit discovery suggests new path in Parkinsons research 13525 2Female Incontinence Surgeries Look Equally Effective 72369 1Female Incontinence Surgeries Look Equally Effective 72369 2Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences 16386 1Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences 16386 2
... Women who have had two or more induced abortions have ... not currently understood to what degree physical activity during pregnancy ... in two new studies from the Norwegian Institute of Public ... Child Cohort Study (MoBa). , The new results from ...
... by North Carolina State University has made a breakthrough that ... other revolutionary medical implants. The researchers have found that the ... create new devices that can be implanted into the human ... hemo-dialysis membranes that can scrub impurities from the blood. , ...
... Lecture was established in 1990 to emphasize to the ... molecular sciences play in our lives. Ullyot Lectures are ... lecturers are distinguished in their fields, nationally recognized, and ... year,s lecture will be given by Bernard Bigot, high ...
Other Biology News:Previous abortions and exercise: Do they affect pregnancy? 2Previous abortions and exercise: Do they affect pregnancy? 3NC State finds new nanomaterial could be breakthrough for implantable medical devices 2